ExodusPoint Capital Management LP Has $26.02 Million Stock Holdings in Astrazeneca Plc $AZN

ExodusPoint Capital Management LP grew its position in shares of Astrazeneca Plc (NYSE:AZN) by 889.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 148,255 shares of the company’s stock after purchasing an additional 133,268 shares during the quarter. ExodusPoint Capital Management LP’s holdings in Astrazeneca were worth $26,019,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in AZN. Arrowstreet Capital Limited Partnership boosted its stake in shares of Astrazeneca by 552.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,547,597 shares of the company’s stock valued at $973,603,000 after purchasing an additional 4,697,895 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Astrazeneca by 344.6% during the third quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock valued at $266,841,000 after purchasing an additional 2,695,793 shares in the last quarter. Citigroup Inc. boosted its stake in shares of Astrazeneca by 65.3% during the fourth quarter. Citigroup Inc. now owns 6,154,760 shares of the company’s stock valued at $1,080,160,000 after purchasing an additional 2,431,890 shares in the last quarter. Holocene Advisors LP boosted its stake in shares of Astrazeneca by 41.8% during the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after purchasing an additional 1,807,565 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich boosted its stake in shares of Astrazeneca by 11,190.9% during the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock valued at $317,107,000 after purchasing an additional 1,790,874 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AZN. Barclays reissued a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. UBS Group restated a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Finally, DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Astrazeneca currently has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Price Performance

Shares of AZN opened at $178.79 on Wednesday. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The company has a market capitalization of $277.29 billion, a price-to-earnings ratio of 26.85, a price-to-earnings-growth ratio of 1.54 and a beta of 0.25. The business has a 50-day moving average of $188.26 and a 200-day moving average of $186.16.

Astrazeneca (NYSE:AZN) last issued its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. As a group, equities research analysts anticipate that Astrazeneca Plc will post 9.39 earnings per share for the current year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.